Application note: Faster and more reliable quantification of oligonucleotide interaction with human serum albumin using MST
Antisense oligonucleotides are an emerging therapeutic option for treating diseases with known genetic origin.
The interaction of these oligonucleotides with proteins such as human serum albumin (HSA) and other plasma proteins determines their pharmacokinetics and pharmacodynamics and affects their absorption, distribution, metabolism and excretion (ADME). During development, the goal is to enhance the interaction with proteins involved in transport and absorption.
Currently, the most commonly used method for the quantification of interaction between the oligomers and HSA is the electrophoretic mobility shift assay (EMSA). However, EMSA presents many disadvantages: dissociation can occur since samples are not at equilibrium during the run, the use of radioactive material (32P) and inconvenient detection and subsequent quantification.
Developing safer and more effective oligonucleotide drug candidates requires a fast, easier and more reliable method to monitor and characterise their protein binding properties.
Related content from this organisation
- Bispecific antibodies: the next generation of immuno-oncology drugs
- Oncology meets immunology – antibody-mediated regulation of the immune response
- Antibody therapeutics for COVID-19
- Defusing antibody neutralisers in AAV gene therapy
- Expert view: Increasing the efficiency of biologics development: the secret is precise and reliable stability characterisation of candidate molecules